In TNM (Tumor, Node, Metastasis) classification and staging of breast cancer, what is the incorrect statement regarding fibroadenoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The incorrect statement regarding fibroadenoma is that it is a premalignant lesion. Fibroadenomas are mostly benign breast lesions, and they are not included in the TNM classification system, which is specifically designed for malignant tumors. The TNM system categorizes cancerous breast tumors based on the size of the primary tumor (T), involvement of regional lymph nodes (N), and presence of distant metastasis (M) 1. Since fibroadenomas are non-cancerous growths composed of breast tissue and stromal components, they do not require cancer staging. They are typically managed through observation or surgical excision depending on their size, symptoms, and patient preference 1. Some key characteristics of fibroadenomas include:

  • Mostly benign
  • Mostly mobile
  • Can be diagnosed by mammogram, although this method may not distinguish them from phyllodes tumors in some cases
  • May be huge in size Fibroadenomas are the most common benign breast tumors in women under 30 years of age and are characterized by their firm, rubbery texture and mobility within the breast tissue. While they may require clinical attention, their benign nature excludes them from cancer staging protocols like TNM. It's worth noting that phyllodes tumors, which can be benign, borderline, or malignant, may present similarly to fibroadenomas but require a different management approach, including excisional biopsy to determine their nature 1.

From the Research

Incorrect Statement Regarding Fibroadenoma

The incorrect statement regarding fibroadenoma is:

  • Premalignant lesion

This is because fibroadenomas are considered benign breast lesions and are not typically considered premalignant lesions. According to 2, the consensus view is that women with fibroadenomas are not at significant increased risk of developing breast cancer. However, it is worth noting that while rare, malignant transformation of a fibroadenoma can occur, as discussed in 3.

Characteristics of Fibroadenoma

Fibroadenomas are characterized by the following:

  • Mostly benign 2
  • Mostly mobile 4
  • Can be diagnosed by mammogram, but diagnosis is based on the combination of clinical examination, imaging, and non-surgical tissue biopsy (the triple test) 2
  • May be huge, as in the case of giant fibroadenomas 5

Diagnosis and Management

Diagnosis of fibroadenoma is typically made using a combination of clinical examination, imaging (such as mammography and ultrasound), and tissue biopsy 2, 4. Management options include surgical excision, observation, and conservative management 2, 4. High intensity focused ultrasound (HIFU) has also been explored as a non-invasive treatment option for fibroadenomas 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Fibroadenoma of the breast.

The Medical journal of Australia, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.